C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
- Determine the role of positron emission tomography using carbon-11 acetate (AC-PET) in
the initial and subsequent management of patients with prostate cancer at intermediate
or high risk for recurrence after initial curative therapy.
- Compare the value of AC-PET in predicting recurrence of prostate cancer with that of
conventional approaches (e.g., pre-operative clinical staging, prostate-specific
antigen, Gleason score, prostate and lymph node histology) in these patients.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Tissue Biopsy of metastatic site(s)
Patients will undergo needle biopsy of positive metastatic findings on C11- Acetate PET/CT
Assessed within 30 days following AC-PET
Fabio Almeida, MD
Medical Director, Arizona Molecular Imaging Center
United States: Food and Drug Administration
|Arizona Molecular Imaging Center||Phoenix, Arizona 85040|